Sol-Gel Technologies (SLGL) Retained Earnings (2015 - 2026)
Sol-Gel Technologies (SLGL) posted quarterly Retained Earnings of -$240.7 million for Q1 2026, little changed year-over-year from -$241.8 million in Q1 2025, and down 1.57% quarter-over-quarter from -$237.0 million in Q4 2025.
Analysis
Sol-Gel Technologies (SLGL) Retained Earnings (2015 - 2026) Analysis & Trends
Sol-Gel Technologies (SLGL) has reported Retained Earnings for 11 consecutive years, with -$240.7 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Retained Earnings changed 0.44% year-over-year to -$240.7 million; the TTM figure through Mar 2026 stood at -$240.7 million (changed 0.44% YoY), while the FY2025 annual figure was -$237.0 million, down 2.65% from the prior year.
- Retained Earnings slipped to -$240.7 million in Q1 2026 per SLGL's latest filing, from -$237.0 million in the prior quarter.
- Across five years, Retained Earnings topped out at -$183.7 million in Q1 2022 and bottomed at -$240.7 million in Q1 2026.
- Historically, Retained Earnings has averaged -$218.2 million across 5 years, with a median of -$224.7 million in 2024.
- Annual changes were most pronounced in 2022 — Retained Earnings rose 2.55% — and 2023, when it declined 15.05%.
- Sol-Gel Technologies' Retained Earnings stood at -$193.1 million in 2022, then dropped by 14.11% to -$220.3 million in 2023, then declined by 4.8% to -$230.9 million in 2024, then decreased by 2.65% to -$237.0 million in 2025, then declined by 1.57% to -$240.7 million in 2026.
- Business Quant data shows SLGL's Retained Earnings at -$240.7 million in Q1 2026, -$237.0 million in Q4 2025, and -$234.0 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 5.10 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -4.00 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 13.05 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | -6.33 Bn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 4.38 Bn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 6.57 Bn |
| 10 | Sol-Gel Technologies | 194.01 Mn | 146.08 Mn | - | -244.42 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -244.42 Mn |
| Mar 31, 2026 | -240.74 Mn |
| Dec 31, 2025 | -237.01 Mn |
| Sep 30, 2025 | -234.02 Mn |
| Jun 30, 2025 | -228.08 Mn |
| Mar 31, 2025 | -239.69 Mn |
| Dec 31, 2024 | -230.88 Mn |
| Sep 30, 2024 | -225.04 Mn |
| Jun 30, 2024 | -224.67 Mn |
| Mar 31, 2024 | -226.65 Mn |
| Dec 31, 2023 | -220.30 Mn |
| Sep 30, 2023 | -215.47 Mn |
| Jun 30, 2023 | -209.76 Mn |
| Mar 31, 2023 | -203.33 Mn |
| Dec 31, 2022 | -193.07 Mn |
| Sep 30, 2022 | -187.28 Mn |
| Jun 30, 2022 | -209.76 Mn |
| Mar 31, 2022 | -183.74 Mn |
| Dec 31, 2021 | -178.14 Mn |
| Sep 30, 2021 | -192.17 Mn |